altimmune glp-1 Readout Newsletter: Altimmune, Eli Lilly, CDC, FDA, Boston Altimmune, Inc. Announces Presentation of

Have experienced facial volume loss after significant weight loss

A study of almost 2000 people published in February 2021 has shown that a new, once-a-week weight loss injection can help patients with obesity.

We will continue to monitor the phenomenal up-take of GLP-1 drugs (recognizing its growing pipeline shown in the chart above) and patients perspectives of the use of these medications both those people prescribed them to treat medical obesity and those consumers willing to pay for them out-of-pocket

Which ones the drug hits depends on the patient's biology

GLP-1 drugs have had a pretty wild rise

El uso de medicamentos GLP-1 como semaglutida para bajar de peso se ha duplicado en la ltima dcada, pero su uso ha disminuido entre los diabticos tipo 2, segn un nuevo estudio.